李娜+楊豐文+陸中英+張冬+劉春香+鄭文科

[摘要] 系統(tǒng)評(píng)價(jià)藍(lán)芩口服液治療慢性咽炎的療效和安全性。計(jì)算機(jī)檢索PubMed，Embase，Cochrane Library，CBM，CNKI，VIP，萬方科技數(shù)據(jù)庫，收集藍(lán)芩口服液治療慢性咽炎的隨機(jī)對(duì)照研究，檢索時(shí)限均為從建庫至2017年3月，由2名研究者按照納入和排除標(biāo)準(zhǔn)獨(dú)立進(jìn)行文獻(xiàn)篩選、資料提取，用Cochrane偏倚評(píng)估手冊(cè)進(jìn)行質(zhì)量評(píng)價(jià)并交叉核對(duì)。采用RveMan.5.3軟件進(jìn)行數(shù)據(jù)分析。共納入13個(gè)隨機(jī)對(duì)照試驗(yàn)，共計(jì)1 642例慢性咽炎患者。Meta分析結(jié)果顯示： ①有效率：藍(lán)芩口服液治療組優(yōu)于對(duì)照組（常規(guī)治療或其他藥物治療）；②IL-2：藍(lán)芩口服液治療組優(yōu)于對(duì)照組（MD及95% CI，2.20[1.91，2.48]，P<0.000 01）；③TNF-α：藍(lán)芩口服液治療組優(yōu)于對(duì)照組（MD及95%CI，0.75[0.60，0.90]，P<0.000 01）；④不良反應(yīng)：無安全性信息報(bào)告?；诂F(xiàn)有臨床證據(jù)，藍(lán)芩口服液治療慢性咽炎的有效率優(yōu)于常規(guī)治療或其他藥物治療。但由于納入研究的方法學(xué)質(zhì)量普遍較低，需要嚴(yán)格方法學(xué)設(shè)計(jì)和質(zhì)量控制的臨床研究提供高質(zhì)量的證據(jù)。

[關(guān)鍵詞] 藍(lán)芩口服液；慢性咽炎；隨機(jī)對(duì)照試驗(yàn)；系統(tǒng)評(píng)價(jià)；Meta分析

Lanqin oral liquid for the treatment of chronic pharyngitis：

systematic review and Meta-analysis of randomized clinical trials

LI Na1，YANG Feng-wen1，LU Zhong-ying1，ZHANG Dong2，LIU Chun-xiang2，ZHENG Wen-ke2

（1. Tianjin University of Traditional Chinese Medicine，Tianjin 300193，China；

2. Center for Evidence-Based Medicine，Tianjin University of Traditional Chinese Medicine，Tianjin 300193，China）

[Abstract] To systematically assess the effectiveness and safety of lanqin oral liquid for the treatment of chronic pharyngitis. Databases including PubMed，Embase，The Cochrane Library，SinoMed，CNKI，VIP and Wanfang Data were electronically searched in March 2017 for randomized controlled trials（RCTs） on Lanqin oral liquid for the treatment of chronic pharyngitis. Two authors independently screened literature，extracted data，and assessed the risk of bias of included studies. Then，meta-analysis was performed by RevMan 5.3 software. Thirteen RCTs were included with a total of 1 642 patients. The results of meta-analysis showed that the efficiency of lanqin oral liquid were significantly higher than those of conventional therapy or other treatments；Besides，lanqin oral liquid could significantly increase the amount of IL-2 further more，lanqin oral liquid could significantly reduce the amount of TNF-α. Safety of lanqin oral liquid was not concerned by any RCT. Current evidence indicates that the efficiency of lanqin oral liquid was better than conventional therapy or other treatments. Due to the poor quality of the included studies，the above conclusion should be verified by more RCTs of high quality.

[Key words] Lanqin oral liquid；chronic pharyngitis；randomized controlled trial；dystematic review；Meta-analysis

慢性咽炎是指咽喉部黏膜的慢性炎癥，是臨床上常見病癥，具有病程長(zhǎng)、反復(fù)發(fā)作等特點(diǎn)，主要是因細(xì)菌、病毒等因素長(zhǎng)期刺激所致，多發(fā)于成年人[1]。慢性咽炎患者的臨床表現(xiàn)主要有咽部疼痛、有異物感、發(fā)癢及咳嗽等，尤其是在晨起刷牙時(shí)會(huì)出現(xiàn)反射性的惡心、欲吐等現(xiàn)象，影響患者及其家屬的生活質(zhì)量[1]。目前藍(lán)芩口服液治療慢性咽炎的臨床研究較多，但缺乏系統(tǒng)的分析和評(píng)價(jià)。本研究旨在對(duì)藍(lán)芩口服液治療慢性咽炎的臨床效果進(jìn)行系統(tǒng)評(píng)價(jià)，以期為藍(lán)芩口服液在臨床的正確應(yīng)用提供依據(jù)。